title: Effects of zinc methionine and zinc oxide on performance, blood characteristics, and antibody titer response to viral vaccination in stressed feeder calves.
abstract: Ninety steers with an average weight of 214 kg were purchased at 2 feeder calf sales and transported 70 to 100 km. On arrival at the feedlot, steers were weighed and identified, blood was withdrawn, and the steers were vaccinated against bovine herpesvirus-1 (BHV-1) and parainfluenza3 (PI3), using a modified live vaccine, and randomly assigned to treatment groups. Treatments were: control (no supplemental zinc; zinc methionine; and zinc oxide. The control diet contained 26 mg of zinc/kg diet, and zinc was added in treatments 2 and 3 to provide 25 mg of supplemental zinc/kg diet. Neutralizing antibody titers were determined on serum samples taken on days 0 and 14 as a measure of the immune response to BHV-1 and PI3 vaccination. Weight gains for the 28-day study were similar across treatments. Dry matter intake tended to be higher in steers fed supplemental zinc from either source, because steers fed zinc methionine and zinc oxide consumed 5.2 and 4.4% more feed, respectively, than controls. Antibody titers against BHV-1 tended to be higher in steers supplemented with zinc methionine on day 14. Differences between treatments were not found for PI3 titers. Mortalities did not occur and morbidity rate was low.
authors.affiliation: Department of Animal Science, College of Agriculture and Life Sciences, North Carolina State University, Raleigh 27695-7621.
authors.forename: J W
authors.initials: JW
authors.lastname: Spears
authors.forename: R W
authors.initials: RW
authors.lastname: Harvey
authors.forename: T T
authors.initials: TT
authors.lastname: Brown
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D002417:Cattle; D002418:Cattle Diseases / Q000188:drug therapy* / Q000517:prevention & control; D004435:Eating / Q000187:drug effects; D007242:Herpesvirus 1, Bovine / Q000276:immunology; D008297:Male; D008715:Methionine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D009942:Organometallic Compounds / Q000494:pharmacology / Q000627:therapeutic use*; D010224:Parainfluenza Virus 3, Human / Q000276:immunology; D011897:Random Allocation; D013312:Stress, Physiological / Q000150:complications / Q000188:drug therapy / Q000662:veterinary*; D014765:Viral Vaccines / Q000276:immunology; D015430:Weight Gain / Q000187:drug effects; D015032:Zinc / Q000097:blood; D015034:Zinc Oxide / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000914:Antibodies, Viral; D009942:Organometallic Compounds; D014765:Viral Vaccines; C074508:zinc methionine; D008715:Methionine; D015032:Zinc; D015034:Zinc Oxide